Smithfield Bioscience Tackles Human Organs for Transplantation
Smithfield Foods, the largest pork producer and processor in the world, has launched Smithfield Bioscience to use by-products from the meat production process for the development of pharmaceuticals, nutraceuticals, and medical device solutions.
Smithfield Bioscience will explore new methods and technologies for addressing concerns such as tissue regeneration and the availability of viable human organs for transplantation.
One of Smithfield Bioscience’s first projects is the participation in the Advanced Regenerative Manufacturing Institute, a public-private U.S. manufacturing initiative that develops technologies and manufacturing processes for cells, tissue, and organ development. With funding from the Department of Defense, the consortium is initially focused on technologies that would enable the repair and replacement of human tissue of soldiers injured in combat.
Smithfield Bioscience is also working with Harvard Medical School and Columbia University on the research and development of immunology therapies.
“With these capabilities, our vertical integration and a reputation for transparency and quality, Smithfield Bioscience is well positioned to help the U.S. medical and pharmaceutical industry achieve significant, scalable developments in biologics,” says Courtney Stanton, vice president of the new Bioscience Group for Smithfield Foods.